ABSTRACT
A multidisciplinary panel of 18 physicians and 3 non-physicians from eight countries (Sweden, UK, Argentina, Australia, Italy, Finland, Norway, and the USA) reviewed the literature on diagnosis and management of adult coeliac disease (CD). This paper presents the recommendations of the British Society of Gastroenterology. Areas of controversies were explored through phone meetings and web surveys. Nine working groups examined the following areas of CD diagnosis and management: classification of CD; genetics and immunology; diagnostics; serology and endoscopy; follow-up; gluten-free diet; refractory CD and malignancies; quality of life; novel treatments; patient support; and screening for CD.

INTRODUCTION
Objective
The aim was to create updated guidelines for the management of adult coeliac disease (CD), but non-coeliac gluten sensitivity (NCGS) was not considered.

Development of the guidelines
The British Society of Gastroenterology (BSG) guidelines on the management of adult CD were originally published in 1996. Recently, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) published updated guidelines for paediatric CD, but international guidelines for adult CD are scarce since the NIH consensus on CD in 2005 (despite more than 4000 PubMed publications about CD in the last 8 years). As a result, the Clinical Services and Standards Committee of the BSG commissioned these guidelines, subject to rigorous peer review and based on a comprehensive review of the recent literature, including data from any available randomised controlled trials, systematic reviews, meta-analyses, cohort studies, prospective and retrospective studies.

A multidisciplinary panel of 18 physicians from eight countries (Sweden, UK, Argentina, Australia, Italy, Finland, Norway, and the USA), a dietitian and a representative and a patient advocate from Coeliac UK reviewed the literature on the management of CD. These individuals were involved in the original stakeholder meetings and with revision of the manuscript.

Intent and levels of evidence
All aspects of the contemporary diagnosis and management of patients with adult CD were considered. PubMed literature was searched from 1900 to 2012 to obtain evidence for these guidelines. Also there was input from all authors who have considerable expertise and experience in diagnosis and management of CD. The panel of international experts previously collaborated in the publication of definitions of CD and were invited by the BSG for the development of these guidelines. Subject to rigorous peer review and based on a comprehensive review of the recent literature, including data from any available randomised controlled trials, systematic reviews, meta-analyses, cohort studies, prospective and retrospective studies.

The current literature of review papers was examined, focusing on 10 reviews to explore gaps in current reviews on CD. Nine working subgroups were then formed that examined the following areas of CD management: classification of CD: FB, MH, DSS, CC; genetics and immunology: KEAL, DaVH, PJC; diagnostic criteria, serology and endoscopy in the investigation of CD: MMW, JAM, FB, PHRG, JFL, KEAL; follow-up: DAL, PHRG, JCB, JFL; gluten-free diet (GFD): PJC, KK, CC, GLS; refractory CD (RCD) and complications: FZ, FB, DAL, PHRG; quality of life (QoL): GLS, JCB, TRC, FZ; novel therapy: JCB, KEAL; screening for CD: TRC, KK, JAM, JFL. The working groups wrote the sections, which were subsequently internally reviewed. Each final fully written and
referred section was then released to all group members for review by teleconference and email correspondence. Thereafter JFL created the first draft of the guidelines by amalgamating all documents. All authors then helped revise this draft until final document consensus was reached.

Between January 2012 and February 2013, six web surveys were performed using the web site ‘survey console’ (http://www.surveymonkey.com) to explore issues including coeliac topics of controversy; the role of endoscopy; the role of histopathology and serology in the diagnosis of CD; and follow-up of patients, including the use of follow-up biopsy. The web surveys were for the coauthors/Guidelines Development Group (GDG) members. Survey results were then discussed at teleconference and used to inform the direction of recommendations and outline areas where the GDG were not concordant. Disagreements were solved through discussion.

Studies used as a basis for these guidelines are graded according to the quality of evidence using the Oxford Centre for Evidence-based Medicine levels of evidence.18

Strength of recommendations
A. Directly based on category I evidence, for example, from systematic reviews and randomised controlled trials. This is the strongest recommendation of the four grades listed.
B. Directly based on category II or III evidence or extrapolated recommendation from category I evidence. This includes evidence from controlled non-randomised studies or time series; or indirect evidence from systematic reviews or randomised controlled trials.
C. Directly based on category IV evidence or extrapolated recommendation from category II or III evidence. This also includes evidence from non-experimental studies such as cohort studies or case–control studies.
D. Directly based on category V evidence or inconclusive or inconclusive studies of any level. This includes evidence from expert committees and respected authorities.

BACKGROUND
CD is an immune-mediated small intestinal enteropathy that is triggered by exposure to dietary gluten in genetically predisposed individuals.7 Samuel Gee is credited with the first clinical description of CD in 1887, although Aretaeus of Cappadocia may have described the disease in the first century AD. In the 1930s and 1940s, Dicke demonstrated (then published in 1953) that a wheat-free diet was the key to management. The first non-classical CD8 was described in 1957 by the coauthors of this project, participants of the so-called Oslo group who first convened at the 2011 meeting on CD in Oslo7 collaborated with representatives of the BSG to write guidelines for the management of CD in adults. These guidelines will enable physicians, dietitians, and other healthcare personnel to provide better care for their patients.

During our previous review on definitions of CD and related concepts,7 we realised that there was a need for a consensus paper on modern management and diagnosis of CD. In this project, participants of the so-called Oslo group who first convened at the 2011 meeting on CD in Oslo7 collaborated with representatives of the BSG to write guidelines for the management of CD in adults. These guidelines will enable physicians, dietitians, and other healthcare personnel to provide better care for their patients.

GENETICS, IMMUNOLOGY AND TRIGGER FACTORS
Environmental factors are important in CD and ingestion of gluten is a prerequisite for the development of CD. Children breastfed at and beyond gluten introduction may be at lower risk of developing CD in childhood, although research is not consistent.47 Conversely, large amounts of gluten or gluten exposure without ongoing breastfeeding may increase the risk of future CD.48 49 Gastrointestinal infections, drugs, interferon α and surgery have also been implicated as trigger factors.47 50 51

The factors leading to the breakdown of tolerance to gluten are not known, but local pro-inflammatory changes are of paramount importance.52 A high prevalence (10%) among first-degree relatives of patients with CD53 and a greater concordance rate in monozygotic twins (~75%)54 than in dizygotic twins indicates a strong genetic component.

CD shows a very strong association with a particular HLA variant termed HLA-DQ2.5.55 This molecule is encoded by the DQA1*05:01 and DQB1*02:01 genes in cis configuration on the DR3 haplotype. Thus most patients are DR3, DQ2 positive. A smaller subset of patients with CD express a very similar DQ2.5 molecule encoded by a combination of DR5 and DR7 positive haplotypes, in this situation by the genes in trans position. While the proportion of individuals with CD who are DQ2.5 positive varies in different geographical areas it is generally ≥90%. The majority of the remaining patients are HLA-DQ8 positive (DR4, DQ8 haplotype).55

Genome wide association studies have so far identified 40 loci outside of HLA with genes predisposing to or protecting against CD.57–58 Most of these genes have immunological functions and are related to B-cell and T-cell functions. Each of the non-HLA genes contributes little to genetic risk. With a population prevalence of 1% and a heritability of 50%, the 39 non-HLA loci account for 14% of the genetic variance whereas HLA in comparison accounts for 40%.59

The most striking morphological features of the active coeliac lesion are the infiltration in the epithelium of T-cell receptor α/β and γ/δ expressing CD8 positive T cells, natural killer cell like T cells, and the dense population in the lamina propria of plasma cells and activated antigen presenting cells.\textsuperscript{59, 60} Although numerically not dominant, CD4 gluten reactive T cells (T-cell receptor α/β expressing)\textsuperscript{61, 62} are crucial in the pathogenesis of CD and are not found in people without CD.\textsuperscript{63–65}

The CD4, gluten-specific T cells in the lamina propria invariably recognise gluten presented by the disease-associated HLA-DQ2 and HLA-DQ8 molecules\textsuperscript{61–63} and recognise gliadin peptides that have been modified by tissue transglutaminase 2 (TG2). This modification (glutamine to glutamic acid deamidation process) introduces negative charges.\textsuperscript{66} These modifications produce peptides that bind with much higher affinity to the HLA-DQ2 and HLA-DQ8 molecules.\textsuperscript{67} Patients with CD who are untreated typically have high titres of antibodies against the endomysium antigen (EMA test), also shown to be the extracellular enzyme tissue TG2.\textsuperscript{68} On exposure to gluten, plasma cells produce antibodies to tissue transglutaminase (IgA-TG2)\textsuperscript{69} and deamidated gliadin peptides (IgA-DGP\textsuperscript{70} and IgG-DGP\textsuperscript{71}).

Untreated and treated CD are characterised by an increase in \(\gamma/\delta\) intraepithelial lymphocytes (IELs), although in treated disease, the IEL count is close to that in healthy individuals.\textsuperscript{72}

### DIAGNOSTICS

Diagnosis of CD is by serology and duodenal biopsy, ideally with the patient on a normal, that is, gluten-containing diet. Biopsy remains essential for the diagnosis of adult CD and cannot be replaced by serology. Exceptions are patients with coagulation disorders and pregnant women, in whom biopsy cannot be replaced by serology.\textsuperscript{1212} Exceptions are patients with coagulation disorders and pregnant women, in whom biopsy cannot be replaced by serology.\textsuperscript{1212}

The diagnosis of CD is readily established in those who, while consuming a gluten-containing diet, have positive serology and a duodenal biopsy with obvious coeliac histology (increased intraepithelial lymphocytosis, crypt hyperplasia and villous atrophy; table 1). These patients can immediately initiate a GFD with confidence.

CD can also be suspected in patients with mild gastrointestinal symptoms, associated conditions or those at genetic risk.\textsuperscript{3} Such patients should be investigated initially with serology and if this is positive (or if there is still a high index of suspicion as among symptomatic first-degree relatives\textsuperscript{74}), then undergo upper endoscopy and duodenal biopsies.

However, in some cases the diagnosis of CD may not be straightforward, for example, patients are already on a GFD and therefore antibodies are negative, biopsies were not oriented correctly (this could lead to false-negative or false-positive villous atrophy) or show solely intraepithelial lymphocytosis (lymphocytic duodenitis)\textsuperscript{74} without architectural changes. In these situations, the patient needs to be maintained on a gluten-containing diet and further evaluated with additional testing and, if necessary, referred to a centre or clinician with a specific interest in CD.

The diagnosis of CD is illustrated in table 1.

### Serology in CD diagnosis

Serological detection depends on the presence of specific endomysial antibodies (EMAs, also called AEs), IgA anti-tissue transglutaminase (TTG) or IgG-DGP may also represent CD (‘probable CD’), and in these circumstances a trial with GFD may be considered to further support the diagnosis of CD. HLA status may also aid diagnosis. Differential diagnoses of lymphocytic duodenitis should be ruled out if there is no response to GFD (see table 2).

The diagnosis of CD is readily established in those who, while consuming a gluten-containing diet, have positive serology and a duodenal biopsy with obvious coeliac histology (increased intraepithelial lymphocytosis, crypt hyperplasia and villous atrophy; table 1). These patients can immediately initiate a GFD with confidence.

### Table 1

<table>
<thead>
<tr>
<th>IgA-TG2</th>
<th>Total IgA</th>
<th>IgG-TG2</th>
<th>IgG-DGP</th>
<th>EMA</th>
<th>HLA</th>
<th>Biopsy showing CD type histology*</th>
<th>Coeliac status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient on a gluten-containing diet, IgA-TG2 or IgA-DGP, or IgG-DGP, EMA positive and the biopsy shows villous atrophy</td>
<td>+</td>
<td>Normal or ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Coeliac if VA, otherwise probably coeliac</td>
</tr>
<tr>
<td>For patients for whom the above criteria are not fulfilled, please see below</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>Coeliac if VA, otherwise probably coeliac</td>
</tr>
<tr>
<td>–</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>+</td>
<td>–</td>
<td>Potential celiac</td>
</tr>
<tr>
<td>+ (usually low titre)</td>
<td>–</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>–</td>
<td>–</td>
<td>Not coeliac</td>
</tr>
<tr>
<td>Normal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>Not coeliac</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>Not coeliac</td>
</tr>
<tr>
<td>Normal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>Not coeliac</td>
</tr>
<tr>
<td>Low/absent</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>IgA deficient and celiac if biopsy shows VA. Otherwise IgA deficient and probable coeliac</td>
</tr>
<tr>
<td>Low/absent</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>IgA deficient, not coeliac</td>
</tr>
<tr>
<td>Low/absent</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>?post infectious diarrhea</td>
</tr>
<tr>
<td>Combined immune deficiency syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Biopsy showing CD type histology = villous atrophy, crypt hyperplasia but must have intraepithelial lymphocytosis, IELs≥25/100 enterocytes.
†A duodenal biopsy may be negative when the lesion is only present in the jejunum.
‡And the patient does not respond to a gluten-free diet.
\(\gamma/\delta\) T cells, transglutaminase 2; VA, villous atrophy (Marsh 3).
transglutaminase antibodies (IgA-TG2, also called a-TTG, TTA) and/or deamidated antigliadin antibodies (DGP, either IgA or IgG isotype).7,8 IgG-TG2 is primarily useful in patients with known IgA deficiency.7,8

There is continuing debate on the sole use of non-invasive tests to diagnose CD. Recently ESPGHAN proposed new guidelines for the diagnosis of CD in children. It suggests that in symptomatic paediatric patients1 in whom the IgA-TG2 level exceeds 10 times the upper limit of normal, EMA antibodies are positive on a separately taken blood sample, and HLA-DQ2 or HLA-DQ8 are positive, then biopsies do not need to be performed to confirm the diagnosis of CD.1 In adults, this strategy has also been proposed77; however, there are very strong arguments for retaining the biopsy as gold standard for the diagnosis of CD. A recent study from the (UK) National External Quality Assessment Service centre states that not all commercial IgA-TG2 kits are reliable and the ESPGHAN guidelines are therefore not translatable for use in all centres and should not be used in the UK.78 Also, 2% of patients with CD are IgA deficient (0.2% of the population in general) and as usual serology tests for IgA-TG2 and EMA are IgA based, this may lead to false negatives and a reduction in test sensitivity. If patients are known to be IgA deficient, IgG-TG2 or IgG-DGP antibodies can be used, or alternatively, such patients should proceed directly to biopsy.79

A combination of immunoassays offers the best sensitivity if either a positive IgA-TG2 or IgG-DGP is considered a positive detection test. The combination of IgG-DGP and IgA-TG2 is particularly useful as an addition to detection of patients with CD who are IgA deficient. IgG-DGP was able to detect a few more IgA-sufficient patients who were missed by IgA-TG2 alone.76

There are now several point-of-care tests commercially available, which allow both immediacy and the ability to use them in a physician office/primary care setting. However, there is a relative paucity of data on the sensitivity and specificity of such tests by comparison to the gold standard of duodenal biopsy.80 There is concern regarding the use of these tests as patients may start a GFD without a firm diagnosis—which includes biopsy—and further studies should be performed before considering the use of these in everyday practice. One study utilising community health nurses demonstrated a lower than expected sensitivity for CD.81

### Endoscopy in seronegative individuals

The prevalence of seronegative CD is 6–22% of all diagnosed cases.71 82 83 84 One study also found a high degree of variability in EMA values for sensitivity between laboratories,85 and upper endoscopy is generally well tolerated and safe.86 Individuals of white European, Middle Eastern, North African or North Indian origin who undergo upper endoscopy for anaemia, weight loss or diarrhoea should therefore have duodenal biopsies performed, irrespective of whether they have had serology for CD. These features may well indicate that CD or an alternative mucosal cause of malabsorption is present.87

![Table 2](image)
Role of HLA in the diagnosis of CD

CD is associated with specific HLA types in virtually all populations in which this has been tested, and is associated with the carriage of the gene pairs that encode DQ2.5 and DQ8.46,89 The diagnostic value of HLA genotyping in patients who may have CD revolves around its high negative predictive value, meaning that patients who lack the appropriate HLA genotype pairs described above are very unlikely to have CD.90 However, the positive predictive value of the HLA genotyping for CD susceptibility is very low as a large proportion of individuals without CD carry either HLA-DQ2 or HLA-DQ8 (the prevalence of DQ2 in the general population varies between 0% and 40% while that of DQ8 varies between 0% and 20% between countries91). In family screening, DQ2-positive or DQ8-positive relatives (especially siblings) are at a higher risk of CD,53 92 with one study suggesting that DQ2 positivity was associated with a 16-fold increased risk of CD among first-degree relatives.93

Specific use of HLA typing

HLA genotyping may be used in patients with suspected CD but who fail to respond to a GFD. A negative test in this circumstance would indicate that patients are highly unlikely to have CD (<1% of patients with CD are negative for DQ2 and DQ889) and thus the clinician can direct diagnostic efforts elsewhere. HLA typing may similarly be used in patients who are self-treated on a GFD and never had appropriate testing for CD before changing their diet. HLA typing may have an adjunctive role to identifying individuals who are not genetically at risk of CD and in whom further evaluation for CD is not necessary, saving a large number of repeated tests for CD in patients who would otherwise have to undergo testing because they have symptoms and a first-degree relative with CD.94

Biopsy and endoscopy in CD

There are endoscopic markers of villous atrophy described—scalloping or reduction of duodenal folds and nodularity—but these are not sensitive enough to preclude a biopsy,95 and a normal endoscopic appearance may occur in the presence of villous atrophy.96–98 Therefore, the endoscopic appearance of the duodenum should not determine whether biopsy is performed.

Biopsy of the duodenum for a diagnosis of CD should be performed irrespective of the prior performance of serological tests, if the patient exhibits symptoms or signs of CD, such as diarrhoea, weight loss or anaemia. Biopsies can be mounted on fibre-free paper to aid orientation,99 or alternatively biopsies could be free floated in formalin. Consultation with the histopathology laboratory is recommended to agree on specimen presentation.

The villous atrophy may be patchy in CD; hence multiple biopsies from the bulb and the more distal duodenum are recommended. The taking of at least four biopsy specimens is associated with a doubling of the diagnostic rate compared with patients undergoing a lower number of biopsies (less than four).100 In patients with persistently positive coeliac serology but a normal mucosa, repeat small intestinal biopsy should be considered, including biopsies from the jejunum.101 Video capsule endoscopy may support a CD diagnosis in this setting.102

A diagnosis of CD has implications for family members, as overall, around 10% of first-degree relatives53 may be affected and there could be uncertainty in pursuing this diagnosis in the family if the index case does not have a definite CD diagnosis. Within an adult population the patient may have other indications for an upper endoscopy, for example anaemia, and thus exclusion of other diseases is essential. Upper endoscopy is generally well tolerated by adults and, in contrast to children, can usually be readily performed with mild or even no sedation. Finally histological appearance of the small intestinal mucosa may also predict the risk of certain future complications, such as lymphoma (patients with villous atrophy are at statistically significantly higher risk of future lymphoma than patients with a normal mucosa but positive coeliac serology).103

Nevertheless there are still adult patients who may be unable or unwilling to undergo an endoscopy. Under these circumstances, assessment of the serological assay and/or level of IgA-TG2 (if 10 times the upper limit of normal), positive DGP/EMA, or the use of capsule endoscopy may have a supportive role. The sensitivity of capsule endoscopy to detect CD is similar to that of conventional endoscopy when combined with biopsies. However, it is less invasive, with good specificity and may provide endoscopic images that can then be used to support the diagnosis of CD in conjunction with positive serology. This approach may also be taken in equivocal cases.104,105

Recommendations

- In individuals undergoing an upper endoscopy in whom laboratory tests or symptoms or endoscopic features suggest CD, duodenal biopsy should be considered. (Grade C)
- HLA typing should be used to rule out CD. A positive DQ2.5 or DQ8 can never confirm the diagnosis. (Grade B)
- HLA typing should be used in individuals who are self-treated on a GFD and never had appropriate testing for CD before changing their diet. (Grade B)
- HLA typing can be used to rule out CD, and minimise future testing, in high-risk individuals with CD, for example, first-degree relatives. (Grade B)
- The diagnosis of CD requires duodenal biopsy when the patient is on a gluten-containing diet and for the vast majority of adult patients also positive serology. (Grade B)
- Duodenal biopsy should be retained as the mainstay for the diagnosis of adult CD and cannot be replaced by serology. (Grade B)
- At endoscopy, if there is suspicion of CD, then at least four biopsy specimens should be obtained, including a duodenal bulb biopsy. (Grade C)
- In serologically negative patients showing signs of malabsorption (such as anaemia or diarrhoea) or a family history of CD, a duodenal biopsy should be considered. (Grade C)
Histopathology diagnosis of CD

It is important that pathologists and clinicians appreciate that patients with CD benefit from a GFD regardless of the degree of damage in the small intestine and that minor degrees of histological change suggestive of CD should not be ignored. Marsh described a commonly used classification of this spectrum. This classification has been modified subsequently by Oberhuber and simplified by Corazza and Villanacci. Recently, Rostami and Villanacci defined microscopic enteritis (also called lymphocytic duodenosis, lymphocytic enteropathy, and Villanacci et al published a practical classification with a user-friendly checklist for the histology report of CD.

Some clinicians would prefer a descriptive report, and collaboration between pathologists and gastroenterologists as to the content of the report is valuable. It is important that if serology has not been performed prior to the biopsy, then this must be carried out by the requesting physician on receipt of a histology report suggesting a diagnosis of CD. A biopsy finding of villous atrophy is not specific for CD. Although CD is the commonest cause of villous atrophy, there are other causes (table 2); for this reason the addition of coeliac-specific serology seals the diagnosis. The biopsies must be properly oriented (usually by an experienced laboratory technician) as correct orientation is necessary for assessment of villous height crypt depth ratio (derived from the well oriented fields of the biopsies) (figure 1).

The following features should be stated in the report:

- Number of biopsies (including those from the duodenal bulb).
- The architectural features (normal, partial, sub-total or total villous atrophy).
- Comment on the content of the lamina propria (in CD these are lymphocytes, plasma cells and eosinophils, and occasionally neutrophils, but cryptitis and crypt abscesses should suggest other pathology).
- Presence of Brunner’s glands.
- Evaluation of IELs (with immunocytochemical staining for T cells CD3) in equivocal cases is vital. Counting IELs should be time efficient—simply counting IELs/20 enterocytes at the tips of five villi, or IELs per 50 enterocytes in two villi and summing these are both reliable and sensitive methods using H&E staining methods. The normal count has been variably cited; however, in evidence-based practice and in recent classifications, <25IELs/100 enterocytes should be taken as the norm.
- Use of a simple classification system greatly enhances intra-observer agreement.

Figure 1 Relationship between villous height and crypt depth. CD, crypt depth; IEL, intraepithelial lymphocyte; LD, lymphocytic duodenosis; PVA, partial villous atrophy; TVA, total villous atrophy; VH, villous height. The dots represent IELs.

Other causes of lymphocytic duodenosis and villous atrophy

Lymphocytic duodenosis is a common condition (3.8% of a population negative for coeliac serology) seen in association with infection (particularly Helicobacter pylori), altered immune states, for example, common variable immunodeficiency, autoimmune and chronic inflammatory disorders, drugs and neoplasia. The villous architecture is normal, typically there is no crypt hyperplasia and IELs are ≥25/100 enterocytes. Of note, in a single study 16% of cases of lymphocytic duodenosis were found to have CD, and in 66% a known association was found by further investigation. Similarly there are other causes of villous atrophy in duodenal biopsies, including immune disorders and deficiency, food hypersensitivity, infection, drugs, neoplasia and miscellaneous disorders (table 2). In a study of non-coeliac enteropathy, 70% of patients with this condition were initially diagnosed as having CD.

NOVEL DIAGNOSTIC METHODS

While the current standard tests of serology and conventional histology are usually adequate to reach a diagnosis of CD, there are patients whose tests are equivocal and diagnostic uncertainty remains. Several novel diagnostic approaches have been undertaken. The deposition of IgA antibodies in close proximity to TG2 in the small intestine has shown promise as a way of defining early or potential CD in patients who are seropositive but lack any of the usual histological markers for CD. Recent work from Finland on IgA-TG2 autoantibody deposition in the small intestine in such patients shows promise in delivery of an early...
prediction of development of CD. However, this is currently experimental and the methodology requires tissue sections frozen in liquid nitrogen.\textsuperscript{124} Another diagnostic method merit- ing further evaluation is EmA assay in the culture medium of small intestinal biopsies.\textsuperscript{125, 126} Other investigators have reported their findings using new techniques associated with endoscopy to enhance the diagnosis of CD. These include confocal microscopy, high-resolution magnification endoscopy, optical fiber imaging\textsuperscript{127} and optimal coherence tomography. These novel techniques are still limited by availability, tolerability and cost.\textsuperscript{99} However, the immersion technique and dye enhancement in which the endoscopist instills water or a contrast dye (for example, indigo carmine or methylene blue) into the bowel lumen, with or without the assistance of magnifica- tion endoscopy, enhancing the visualisation of villi\textsuperscript{128} can be readily used and improves visualisation of villi, thus increas- ing the sensitivity for detection of villous atrophy.\textsuperscript{98}

**Dermatitis herpetiformis**

Dermatitis herpetiformis (DH) is the cutaneous manifestation of gluten-sensitive enteropathy precipitated by exposure to dietary gluten.\textsuperscript{125} It is characterised clinically by herpetiform clusters of intensely itchy urticated papules and small blisters distributed on the extensor aspects of the elbows and knees and over the buttocks and on the scalp. The commonest age of onset is between the third and fourth decade, though the condition may occur at any age after weaning. Male patients are affected twice as often as female patients. For the majority of patients the disease is lifelong with varying periods of activity, potentially due to varying degrees of dietary adherence.

The major diagnostic criterion for diagnosis is the presence of granular IgA deposits in the dermal papillae of uninvolved peri- lesional skin as shown by direct immunofluorescence, and the diagnosis should not be made unless this has been confirmed.\textsuperscript{130}

Less than 10% of patients with DH have symptoms or signs of malabsorption but most have evidence of CD that responds to a GFD and relapses on gluten challenge. Patients with DH present with their skin manifestations and are not usually troubled by the underlying small bowel problem at the time of presentation.\textsuperscript{129, 131} Abnormality of the small intestinal mucosa with either total or subtotal villous atrophy is found in approximately 70% of patients with DH.\textsuperscript{132} A further 25% have normal villous architecture with increased IELs.

DH shares with CD an increased risk of developing lymphomas but this seems to be confined to those with severe gut involve- ment. The risk similarly declines with time on a strict GFD.\textsuperscript{133}

Due to rash and itch, dapsone is often initiated. More than 70% of patients on a strict GFD are however able to slowly wean off dapsone over a period of 24 months.\textsuperscript{131}

**FOLLOW-UP**

There is a paucity of data pertaining to adherence to a GFD being improved by follow-up in patients with CD.\textsuperscript{17, 134–138} Only one previous historical study has assessed the impact of regular follow-up (annual review) at a dedicated doctor-led coeliac clinic.\textsuperscript{136} The investigators suggested that adherence was improved by having access and regular follow-up within the setting of a specialist coeliac clinic (improvement in adherence was 97.5% for those under clinic follow-up vs 40.4% for those no longer under follow-up); however this was an observa- tional study and there were likely to be marked biases in referral of cases, it is not possible to be confident that the associations seen were causal. There are no published data assessing the value of this approach or whether adherence to a GFD, QoL, avoidance of complications, or satisfaction with the service is improved by offering a dietitian-led coeliac clinic. One of the key factors relating to adherence is dietetic input and regular follow-up.\textsuperscript{17, 134} Optimally, the clinic should have gastrointes- tinal and dietetic expertise.\textsuperscript{139} Patients should be encouraged to join disease-specific patient support groups if applicable.\textsuperscript{140}

Once the disease is stable and the patients manage their diet without any problems, annual follow-ups should be initiated. The physician should check on intact small intestinal absorption (full blood count, ferritin, \textsuperscript{32} serum folate, \textsuperscript{141} vitamin B12, \textsuperscript{142} calcium, \textsuperscript{143} alkaline phosphatase\textsuperscript{144}), associated autoimmune conditions (thyroid-stimulating hormone and thyroid hormone(s))\textsuperscript{145} and serum glucose.\textsuperscript{146, 147} Liver disease (aspartate aminotransferase/alanine aminotransferase)\textsuperscript{148} and dietary adherence (anti-TG2 or EMA/DGP), although the sensitivity and specificity of the latter\textsuperscript{148, 149} cannot substitute for structured dietary interview.

In follow-up of CD, the key endpoints are normalisation of the health of patients judged by an absence of symptoms, and mucosal healing.\textsuperscript{17, 17} A lack of symptoms\textsuperscript{2, 110, 151} or negative serological markers are not reliable or responsive surrogates of mucosal response to diet. Dickey et al reported that among 32 patients with CD and persistent villous atrophy, EMA had normalised in 27 (84%); while another British study found that 7/16 (44%) individuals with persistent villous atrophy at follow-up biopsy had a normalised TTG.\textsuperscript{149, 152–154}

The proportion of patients who do not achieve full histo- logical recovery on diet varies, with most reports suggesting mucosal healing in 57–76%.\textsuperscript{130, 155–159}

Some experts favour repeat intestinal biopsy after 1 year of dietary therapy; others, however, do not believe a repeat biopsy is essential for coeliac management in typical cases. It is univer- sally acknowledged that there is little evidence to address whether clinical outcomes are significantly altered as a result of re-biopsy and that the cost–benefit analysis of such an approach has yet to be fully established.

**Recommendations**

- Follow-up biopsies may be considered in patients with CD, and are potentially helpful in identifying patients at increased risk of lymphoma. (Grade B)
- Follow-up biopsies are not mandatory if the patient with CD is asymptomatic on a GFD, and has no other features that suggest an increased risk of complications. (Grade C)
- Follow-up biopsies should be undertaken in patients with CD whose condition does not respond to a GFD. (Grade C)

Assessing adherence to the GFD

Whilst the panel of experts agree adherence to the GFD is most important for the health of a patient with CD, there are no evidence-based grade A recommendations regarding the most useful way to assess this. Dietary adherence should guarantee mucosal healing and at least remission of most gastrointestinal symptoms. At present there are no non-invasive biomarkers that indicate complete mucosal recovery and a number of studies indicate a high prevalence of villous atrophy in adult patients with CD who appear to be adherent (see table 3). When specifically questioned, the experts agreed there is a difference between the first-year follow-up of a newly diagnosed patient and long-term follow-up of an adherent patient with stable disease. An adherent patient with stable disease needs less follow-up and testing than a patient with newly diagnosed CD
in whom the GFD has just commenced, and neither the mucosa nor biochemical aberrations have yet normalised.

There are four steps to assess dietary adherence: clinical assessment of symptoms, dietetic review, serum antibodies and follow-up biopsy.

Symptoms
A meta-analysis of seven studies including more than 3000 subjects showed that the presence of gastrointestinal IBS-like symptoms is common in CD. IBS-type symptoms are more common in patients with CD who are not adherent to a GFD (OR 2.69; 95% CI 0.75 to 9.56). However, patients with CD who are also adherent to a GFD are more likely to experience (persistent) symptoms than controls.161

Dietetic review
The second step is a careful dietetic review conducted by a dietitian or dedicated physician. Apart from a visual analogue score which consists of an unmarked line with the anchor sentences ‘I never adhere to my diet’ and ‘I always adhere to my diet’ at each end,162 there are a number of questionnaires evaluating self-reported GFD adherence and food frequency in the English language163–166 that are also available in other languages.167–171

These questionnaires should be augmented by a dietetic review, which is a useful tool to tease out inadvertent gluten intake and to provide education for a balanced and adequate nutrient intake. There is no standard or quality control for dietetic review because local diets and habits require a specific structured interview, which is a useful tool to tease out inadvertent gluten intake and to provide education for a balanced and adequate nutrient intake. The authors do not present an exact percentage (or absolute number of female patients). The percentage 77% is based on reported data that the female:male ratio was 3.3:1.

Table 3  Histological recovery of duodenal mucosa in CD

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Number of patients</th>
<th>Female patients (%)</th>
<th>Median (M)/average (A) follow-up, years</th>
<th>Positive correlation between dietary adherence and mucosal improvement</th>
<th>Main reason for mucosal damage</th>
<th>Histological recovery of duodenal mucosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hutchinson et al156</td>
<td>UK</td>
<td>284</td>
<td>71</td>
<td>1.9 (M)</td>
<td>p=0.014</td>
<td>No</td>
<td>9% poor adherence</td>
</tr>
<tr>
<td>Rubio Tapia et al160</td>
<td>USA</td>
<td>241</td>
<td>73</td>
<td>–*</td>
<td>p&lt;0.01</td>
<td>Yes</td>
<td>Poor adherence/ severe CD at diagnosis</td>
</tr>
<tr>
<td>Lanzini et al159</td>
<td>Italy</td>
<td>465</td>
<td>77†</td>
<td>1.3 (A)</td>
<td>p=0.029</td>
<td>Yes</td>
<td>25% poor adherence</td>
</tr>
<tr>
<td>Ciacci et al158</td>
<td>Italy</td>
<td>390</td>
<td>77</td>
<td>6.9 (A)</td>
<td>p&lt;0.001</td>
<td>Yes</td>
<td>Poor adherence</td>
</tr>
<tr>
<td>Wahab et al163</td>
<td>The Netherlands</td>
<td>158</td>
<td>72</td>
<td>1–2†</td>
<td>No data</td>
<td>NRCD=symptoms</td>
<td>65%</td>
</tr>
<tr>
<td>Kaukinen et al151 (specific study of NRCD)</td>
<td>Finland</td>
<td>591 with NRCD</td>
<td>69% of those with NRCD</td>
<td>0.7 (M)§</td>
<td>p=0.021†</td>
<td>Became symptomatic if NRCD</td>
<td>46% poor adherence</td>
</tr>
<tr>
<td>Tuire et al22</td>
<td>Finland</td>
<td>177</td>
<td>73</td>
<td>7–10¶</td>
<td>No correlation**</td>
<td>Patients asymptomatic</td>
<td>Clinical relevance of persistent IELs with normal villi</td>
</tr>
<tr>
<td>Lebwohl et al154</td>
<td>Sweden</td>
<td>7648</td>
<td>63</td>
<td>1.3 (M)</td>
<td>No data</td>
<td>NRCD</td>
<td>85%</td>
</tr>
</tbody>
</table>

This table is restricted to studies involving at least 100 patients and presents available data on histological recovery of the duodenal mucosa. Comment on table: In adult studies with >100 patients, non-adherence to a gluten-free diet is a major reason for poor outcome. Symptoms are not a reliable predictor of mucosal healing. Antibodies are not good enough to predict small intestinal damage,48 so a follow-up biopsy is important. Lymphocytic duodenosis is common, but not significant in contribution to symptoms, although it correlates with transgression of adherence to diet.

*Authors present mucosal recovery rate according to Kaplan–Meier at 2-year and 5-year follow-up.
†The authors do not present an exact percentage (or absolute number of female patients). The percentage 77% is based on reported data that the female: male ratio was 3.3:1.
‡No absolute follow-up time is reported but first follow-up biopsies were carried out between 1 and 2 years after coeliac diagnosis.
§Median duration in individuals with persistent villous atrophy. The paper contains no data on the follow-up of the 580 with improved mucosa.
¶Median duration was 7 years in those with persistent villous atrophy but 10 years in those with normal mucosa. The abstract of the paper states an average follow-up of 11 years but that figure is not reported in the paper.
++All individuals, also those with persistent mucosal villous atrophy, had a good dietary adherence. Hence, there can be no positive correlation between dietary adherence and mucosal improvement.
* p<0.01 Yes Poor
asymptomatic Clinical relevance of persistent IELs with normal villi
 85%
studies indicating an absolute necessity of follow-up biopsy for perform a follow-up biopsy in asymptomatic patients with nega-

compared with thereafter. Some experts do not routinely

Gluten challenge

IELs were more frequent even 2

–

5 years after coeliac diagnosis

examined follow-up biopsies at roughly 2

–

5 years (table 3). This may be related to costs (economic and psychological) of performing a procedure that in theory should be repeated many times over the years of follow-up as dietary adherence may vary over time.

The authors of this review underline the necessity of disting-

guiding asymptomatic patients in whom clinical improvement,

poor adherence due to occasional lapses is frequent and

consideration of repeat intestinal mucosal biopsy and review of

measurement of vitamin D levels, dietary review of adherence,

levels (and parathyroid hormone for compensatory increase) at

fore be to measure calcium, alkaline phosphatase and vitamin D

maintained at or above 1000 mg per day.196 Bone density

should be measured in those at high risk of osteoporosis; appro-

be noted that patients with CD may have a weaker response to

be considered if not previously given.204 It should also

Vaccination against

is therefore recommended.202

Pneumococcus is therefore recommended.202

However, it is unclear whether vaccination with the conjugated

could result in impaired immunity to encapsulated bacteria, and an increase in such infections has been demonstrated in CD.199–201 Hyposplenism does not seem to correlate with duration of GFD.198

Vaccination against Pneumococcus is therefore recommended.202

–

Meningococcus,

Haemophilus

Hyposplenism198 associated with CD may result in impaired immunity to encapsulated bacteria, and an increase in such infections has been demonstrated in CD.199–201 Hyposplenism does not seem to correlate with duration of GFD.198

Recommendations

▸ Newly diagnosed patients should have vaccination for Pneumococcus. (Grade C)

▸ Bone density should be measured after 1 year of diet in patients who have additional risk factors for osteoporosis or if over the age of 55 years. (Grade D)

▸ Adult patients with CD should have a calcium intake of at least 1000 mg per day. (Grade D)

▸ Patients with CD require follow-up by a dietitian and/or clinician with an interest or expertise in this field. (Grade D)

▸ Patients should have annual haematological and biochemical profiles. (Grade D)

▸ A GFD is the core management strategy for prevention of osteoporosis. (Grade D)
Table 4 CD as a candidate for general population screening

<table>
<thead>
<tr>
<th>WHO criteria</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>That the disease is common and well defined</td>
<td>CD occurs in approximately 1% of the western population,24 111 and is even more frequent in selected populations.20 208</td>
</tr>
<tr>
<td>Screening tests are simple, safe and accurate</td>
<td>Iga-TG2 screening offers high sensitivity and specificity but the positive predictive value does not attain 100%;83 with a consequent risk of false-positive cases.52 208</td>
</tr>
<tr>
<td>The screening test should be culturally acceptable</td>
<td>Screening seems to be culturally accepted in most parts of the world</td>
</tr>
<tr>
<td>Treatment is available</td>
<td>GFD offers symptomatic relief and will often lead to mucosal healing.</td>
</tr>
<tr>
<td>Clinical detection is difficult</td>
<td>The clinical picture of CD varies, and many patients only have minor symptoms,31 208 210 making it difficult to diagnose CD.</td>
</tr>
<tr>
<td>If undiagnosed and untreated the disease will lead to severe complications</td>
<td>The only available treatment is a GFD. The GFD seems to reduce symptoms and the risk of complications in symptomatic patients,211–219 but it is doubtful whether the GFD leads to health gains in asymptomatic patients,81 214–219 although it should be noted that a proportion of patients who first claim to be asymptomatic in fact have symptoms.70 76 It is also unclear if QoL in patients with screen-detected asymptomatic CD is different71 214 217 220–223 from that of the control populations. Without a decrease in pre-diagnostic QoL, institution of a GFD is unlikely to result in improved QoL after diagnosis.</td>
</tr>
<tr>
<td>Testing and treatment is cost effective</td>
<td>Cost effectiveness depends on the duration of symptoms and the risk of complications in untreated versus treated CD. It is not still clear if the risk of complications is substantially lower in diagnosed CD than in undiagnosed CD.</td>
</tr>
</tbody>
</table>

CD, coeliac disease; GFD, gluten-free diet; QoL, quality of life; TG2, transglutaminase 2.

SCREENING FOR CD

Table 4 lists the WHO criteria for general population screening. CD fulfills many of these criteria but not all of them as yet. Our recommendation is active case finding but not mass screening. Given that CD is a common disease (about 1% of the western population22 24) and that there is a therapy (GFD) that most often relieves symptoms, and may even have an effect on the risk of future complications, any patient with signs or symptoms of CD should undergo testing.

In addition, testing should be carried out in high-risk groups such as those with iron deficiency anaemia,224 Down’s syndrome,223 type 1 diabetes mellitus,147 osteoporosis,184 189 226 and IBS when CD is suspected. The coeliac prevalence in these groups typically varies between 2% and 5%.144 227 228

GLUTEN-FREE DIET

The mainstay of treatment of CD and DH is a GFD. The term gluten should be used to indicate not only wheat-based proteins (gliadins), but it also includes those from barley (hordeins) and rye (secalins), and cereal hybrids such as triticale.238 Originally oats were also avoided in the GFD. Earlier research indicates that oats uncontaminated by gluten are probably safe for patients with CD.237 238 This is important because oats contain soluble fibre, are able to lower blood glucose and attenuate insulin response.239 The appearance of symptoms related to introducing oats might be due to cross-contamination. Also a small percentage of patients with CD may be sensitive to oats,240 and develop symptoms or even mucosal damage.241 242 Patients with CD should be educated to avoid cereals and food containing gluten (breakfast cereals, flours, pasta, cakes, biscuits, sauces etc) derived from wheat, barley or rye and food made from gluten-contaminated oats, and encouraged to eat naturally occurring gluten-free foods and alternative sources of starch (corn, rice, potatoes etc). Levels of susceptibility to gluten contamination of food vary among patients with CD. Although it has also been suggested that the acceptable threshold for gluten content in gluten-free products can from the clinical point of view be set at 100 ppm (¼ mg/kg),243 the Codex Alimentarius Commission of the WHO issued new guidelines for gluten content of processed food in 2008 and a law from the European Commission (EC41/2009), effective since January 2012, stipulated that foods labelled as ‘gluten free’ should contain ≤20 parts per million of gluten, and that this gluten content is safe for the coeliac population. The 20 ppm threshold for gluten-free food is also accepted by the US Food and Drug Administration, effective since August 2013. Newly diagnosed patients should be referred to a dietitian to discuss dietary management.243 It is important that they are educated not only to avoid gluten but also to have a sufficient intake of nutrients, vitamins, fibre and calcium present in their GFD.244 Recent data also indicate that a strict GFD might be of help in reaching ideal body weight, whether an individual is underweight or obese at diagnosis.245 Data suggest that adherence to the GFD is better achieved when the patient is well educated and supported by carers and families. However, there is a wide variation in provision of dietary consultation services for patients diagnosed with CD in the world. A survey indicates that dietary support may be underprovided in the UK.246

QUALITY OF LIFE

There has been a growing interest in how patients with CD perceive the impact of their diagnosis, how their psychological state is influenced by the disease and the effect of GFD. Several studies report that patients with CD have lower QoL scores than the general population.229–232

Though some studies have found improved QoL with GFD treatment in symptomatic and screening-detected patients,222 233 others suggest that any benefit of diet is restricted to those presenting with symptomatic disease.214 220 223 Since mood disorders such as anxiety, depression and fatigue are often linked with CD, before and after diagnosis, it is likely that they may contribute to the effect upon QoL. A recent meta-analysis214 223 suggested that depression, but not anxiety, is more common in adults with CD. Also fatigue has been linked to undetected CD.235

Recommendations

- There is insufficient evidence to recommend population screening for CD, however there should be a low threshold for case finding in clinical practice as per National Institute for Health and Care Excellence guidelines.3 (Grade B)
- Symptomatic first-degree relatives of patients with CD should undergo CD testing. (Grade C)
Safe gluten intake?
As shown previously, diagnosis and advice on a gluten-free diet often lead to mucosal recovery, while poor adherence to diet slows or hinders complete recovery.

Whilst contamination of the diet by gluten may be unavoidable and increased IEL counts are associated with less severe nutritional and metabolic consequences than classic CD with villous atrophy, patients may have significant signs and symptoms related to this disorder. A clinical response and mucosal recovery can be achieved by strict adherence to a gluten-free diet. On balance, data support treatment of patients with CD regardless of the degree of mucosal damage.247

A recent review on ‘safe’ gluten levels argues that daily intakes of <10 mg have no effect on mucosal histology;248 whereas definite alterations are caused by a daily intake of 500 mg and observable alterations by 100 mg. A calculated daily intake of 30 mg seems not to harm the mucosa. Therefore, at present, a safe limit could be set between 10 and 100 mg.249

The most comprehensive systematic review (35 studies) suggests that while the amount of tolerable gluten varies among people with CD, a daily gluten intake of <10 mg is unlikely to cause significant histological abnormalities.248

There is extensive research on GFD and how this may influence the clinical course. While a recent study of more than 7000 individuals undergoing follow-up biopsy found no association between persistent villous atrophy (likely to signal poorer dietary adherence) and overall mortality,174 this does not rule out that poor dietary adherence is negative for specific health outcomes, such as autoimmune disease.250 251 Pregnancy outcome (two studies have found poor foetal outcome in pregnant women with undiagnosed CD but not in diagnosed CD41 252), and especially the risk of lymphoma. Most studies on lymphoma risk according to dietary adherence point towards a protective effect from GFD but the studies have so far been small in size,212 253-255 preventing firm conclusions. However, recently Lebwohl et al256 found a statistically significantly increased risk of lymphoma in patients with CD with persistent villous atrophy compared with those with mucosal healing.

A frequent complaint of patients with CD is that they experience limitations in their social life because of difficulty accessing gluten-free meals or concern about the safety of food when eating out. The patients’ worries are justified as a survey shows that chefs’ knowledge about CD is lower than that of the general public.256 Therefore, education about a GFD needs to be directed to catering personnel. Another criticism is that the availability of gluten-free food is clearly limited in more rural areas and shopping for gluten-free food is time consuming. In most countries, high-quality gluten-free products are available in supermarkets or in special health food stores and on the internet, but the cost of gluten-free food is much greater than the equivalent wheat-based foods.257 258

Patient information and support
Patient support should not be a monologue by a physician, but instead a two-way communication involving the patient, and his/her family. Ideally, collaboration between the patient, the patient’s family, an expert dietitian and interested physician should be the setting in which the GFD should be initiated. Family involvement is very important as the disease (including GFD) will inevitably affect family members, but also joining a national coeliac support group can help patients cope with their disease.

Patients need information, reassurance and the opportunity to learn at their pace about the rather challenging demands of a GFD. They particularly need to be encouraged and motivated to adapt to and maintain a GFD. Continued professional engagement in their follow-up care is likely to help sustain that motivation. Unfortunately, many patients report that they are not satisfied with the amount and quality of the information offered by their physician.216 Physicians should inform patients even before the CD diagnosis, offering information about serological testing, and what it means to undergo a small intestinal biopsy. Worries are common in patients awaiting a biopsy259 and the physician should address this anxiety.

Patients may want information about when and where CD occurs, its aetiology and whether it is a common disease or not. Understanding the vital role of GFD in the management of CD is important for dietary adherence.140 Attaining dietary adherence may be particularly difficult in patients identified through screening. Patients with CD often report reduced QoL because of dietary restrictions and this must be taken into account.260-263 Part of the reduced QoL may be due to social restrictions, such as not being able to eat out with friends, and the economic burden from the more expensive GFD.258 264 Patients should also be informed that while most symptoms are likely to go away on a GFD, some symptoms may persist (see section on ‘Non-responsive CD’).

Recommendations

▸ At diagnosis, patients should be encouraged to join their national coeliac support group. In the UK, patients should be advised about gluten-free items on prescription (FP10), details of which are available from http://www.coeliac.org.uk.

Non-responsive CD
After adoption of the GFD, 4–30% of patients with CD report persisting symptoms and are considered to be affected by non-responsive CD (NRCD).265 Once the initial diagnosis of CD has been confirmed, adherence to the GFD should be assessed by an expert dietitian as inadvertent or deliberate gluten exposure is the most frequent cause of NRCD.265 266

After these initial steps, evaluation should be individualised; however assessment for ongoing enteropathy plays a central role, therefore a follow-up biopsy is needed. Small bowel imaging should be performed in any patient with abdominal pain, persisting fever, obstruction, anaemia, gastrointestinal bleeding or unexplained weight loss.267 If duodenal biopsy does not reveal a persistent enteropathy, symptoms are likely to be due to a second condition.265 266

While the GFD is efficacious at controlling the signs and symptoms of CD and improving intestinal histology in most patients, treatment of CD is currently imperfect. Over time, virtually all individuals with CD will have symptomatic exacerbations due to gluten exposure and up to 30% of patients will...
have symptoms severe or chronic enough to visit their treating physician. Comprehensive monitoring of patients with CD requires assessment for NRCD and efficient evaluation for potential aetiologies. NRCD may be considered in three categories. First and most commonly, NRCD is due to continued dietary exposure to gluten. Second, it may be due to a pre-existing or coincidental condition causing symptoms that resemble CD which may have led to the detection of otherwise asymptomatic CD—this includes IBS or colonic malignancy causing anaemia. Finally, it may be due to conditions associated with CD, such as secondary lactose intolerance, pancreatic exocrine insufficiency, small bowel bacterial overgrowth, microscopic colitis and cow’s milk protein sensitivity. Very occasionally a state refractory to gluten withdrawal occurs, referred to as RCD. Figure 2 suggests an outline for investigating patients with NRCD.

In symptomatic patients with ongoing enteropathy and RCD, coeliac-related malignancies and disorders that mimic CD (table 2) must be excluded. RCD is defined as persistent or recurrent malabsorptive symptoms and/or signs with villous atrophy despite a strict GFD for more than 12 months in the absence of other causes of villous atrophy or malignant complications and after confirmation of CD. RCD is subdivided into type I (RCDI) and type II (RCDII). The most important aspect of differentiating RCDI and RCDII is demonstration of a monoclonal population of T cells or aberrant T cells in the latter. There are different methods available for this, including genetic analysis of T-cell receptor clonality, immunohistochemistry and flow cytometry. Most laboratories will employ at least two methods but their relative contributions remain uncertain. Currently there is variation in the criteria used to diagnose RCDII. The two factors that support the diagnosis of RCDII include loss of normal surface markers CD3 and CD8 with preserved expression of intracytoplasmic CD3 and detection of monoclonal rearrangement of T-cell receptor chain. Areas of uncertainty include the use of immunohistochemistry versus flow cytometry for IEL classification and the relative prognosis of patients with discordant IEL and T-cell studies.

Patients with normal CD3 and CD8 expression and no evidence of T-cell monoclonality have RCDI with a good prognosis. Patients with RCDII have a poorer prognosis, due predominantly to nutritional complications and transformation into enteropathy-associated T-cell lymphoma (EATL). Ulcerative jejunoileitis (UJI) is a rare condition characterised by inflammatory ulceration of the small bowel that arises in RCD. The finding of UJI should raise suspicion for lymphoma.
There is no standard treatment for RCD. Elemental diets, systemic steroids, oral budesonide, oral thioguanines including azathioprine are used in RCDI (and sometimes are beneficial), but have limited benefit in RCDII. In RCDII, cyclosporine, cladribine and high-dose chemotherapy with autologous stem cell support have been reported; however, therapy must be individualised and include surveillance for EATL.

EATL is a rare lymphoma strongly associated with RCDII, which carries a poor prognosis with a cumulative 5-year survival of less than 20%. Currently, two groups of EATL are recognised; EATL type I accounts for 80–90% of all cases and is a large cell lymphoma exclusively associated with CD. In contrast, EATL type II has not been associated with CD.

The poor prognosis of EATL is determined by extent of disease at diagnosis, multifocal small bowel involvement, poor general health and presence of complications including perforation that preclude chemotherapy. Presence of RCDII is associated with a poor prognosis compared with isolated EATL in CD without RCDII. There is no proven effective treatment in EATL. Several strategies have been proposed, and patients should be referred to a tertiary centre to optimise their management.

Finally, numerous studies have confirmed the association between CD and B-cell lymphoma and CD and small intestinal adenocarcinoma.

**Recommendations**

- Patients with persistent symptoms despite a GFD should have a follow-up biopsy. (Grade B)
- In symptomatic patients with ongoing enteropathy and RCD, coeliac-related malignancies and disorders that mimic CD must be excluded. (Grade C)
- Small bowel imaging should be performed in any patient with abdominal pain, fever, obstruction, anaemia, gastrointestinal bleeding or unexplained weight loss. (Grade D)
- Patients with RCD should be referred to a tertiary centre to optimise their management. (Grade D)

**Table 5** Novel treatment in CD

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cereal genomics</td>
<td>The high copy numbers in gliadin genes have so far limited attempts to genetically modify cultivars incapable of expressing immunotoxic peptides. RNA interference of protein translation may reduce gliadin expression, with evidence of reduced proliferation of lymphocytes challenged in vitro.</td>
</tr>
<tr>
<td>Prolyl endopeptidases (PEPs)</td>
<td>These endopeptidases have been isolated from microbial sources and may be capable of enzymatic cleavage of the immunotoxic gluten peptides ex vivo. A combination of a gluten-specific endopeptidase (EP-B2 from barley) and a prolyl endopeptidase (subcutaneous PEP from Sphingomonas capsulata) acts synergistically and has been evaluated in a 6-week phase IIa clinical trial against 2 g gluten taken daily.</td>
</tr>
<tr>
<td>Larazotide acetate</td>
<td>Larazotide is a tight junction regulator and maintains intestinal barrier function after gluten challenge. It acts synergistically and has been evaluated in a 6-week phase IIa clinical trial against 2 g gluten taken daily.</td>
</tr>
<tr>
<td>TG2 inhibitors</td>
<td>Candidate peptidomimetic blockers are currently entering clinical trials but no data are available yet. A potential limitation of this drug candidate is that TG2 activity occurs in a number of diseases and a TG2 inhibitor may therefore have unwanted side effects.</td>
</tr>
<tr>
<td>Blocking of the antigen presenting groove of HLA-DQ molecules</td>
<td>No trials yet. Regarded as unpredictable</td>
</tr>
<tr>
<td>Subcutaneous injection of dominant immunotoxic gliadin peptides</td>
<td>Stimulates an immunoregulatory T-cell response or deplete or anergise antigen specific memory T cells. Responses would be specific to the HLA haplotype DQ2 or 8. Ongoing phase II trials.</td>
</tr>
<tr>
<td>Polymer binding agents</td>
<td>No clinical trials performed yet</td>
</tr>
</tbody>
</table>

CD, coeliac disease; HLA, human leucocyte antigen; TG2, transglutaminase 2.

**NOVEL TREATMENT**

The role of non-dietary therapies—as an adjunct or as an alternative to the GFD—has yet to be ascertained. Of the candidate approaches, immunotherapy (including hookworm exposure) is currently explored as an alternative to GFD but, even if successful, is unlikely to benefit all patients. The role of glutenases (prolyl endopeptidases) and tight junction regulators (table 5) are likely to be in reducing the threshold response and optimising the benefits of gluten restriction rather than allowing a normal gluten-containing diet.

Table 5 contains a list of potential novel treatments. None of the available novel treatments can as yet (January 2014) be recommended for use outside clinical trials.

**DISCUSSION**

We recommend testing for CD in those with suggested symptoms or syndromes, especially if they have a first-degree relative with CD. There is not yet sufficient evidence to support indiscriminate general population screening. Specific serology such as IgA-TG2 and IgG-DGP with or without a strategy for determination of total IgA level should be the preferred serologic strategy for detection of CD. Ideally a combination of serology and biopsies done on a gluten-containing diet will then provide the most robust diagnosis of CD. Additional testing may be necessary for those with less than clear-cut results.

We recommend a duodenal biopsy before the diagnosis of CD. This contrasts with the recent ESPGHAN recommendations where a duodenal biopsy is optional in symptomatic paediatric patients in whom the IgA-TG2 level exceeds 10 times the upper limit of normal, EMA antibodies are positive on a separately taken blood sample and HLA typing is positive for DQ2 or DQ8. CD has been linked to a large number of symptoms (table 1 in the ESPGHAN review on paediatric CD lists 16 such.
symptoms and signs with additional symptoms in the text). There is a risk that all symptoms, independent of their origin, may be taken as a sign of CD when the sensitivity and specificity of even gastrointestinal symptoms are moderate in CD. Other reasons to require a small intestinal biopsy prior to diagnosis is that not all commercial IgA-TG2 kits are of high quality, and that alternative diagnoses may be more common, and sometimes serious, in adults with suspected CD. Finally, an initial biopsy is important for the follow-up of patients, especially those whose condition is non-responsive to a GFD.

Adequate (more than four) biopsies should be taken, from the distal duodenum and the duodenal bulb to maximise diagnosis. The threshold for abnormal IELs is ≥25/100 enterocytes, but for a definite diagnosis villous atrophy is required. However, lesser degrees of damage (≥25 IELs but no villous atrophy) combined with positive serology (IgA-EMA, TTG or IgG-DGP) may also represent CD (‘probable CD’).

The treatment of CD is a lifelong and strict GFD. The goal of treatment is to relieve symptoms, achieve mucosal healing, avoid complications of CD, and have a good QoL with a nutritionally complete GFD. This is best achieved when patients are motivated and receive expert information in a collaborative way, with resources including expert dietitians and interested medical care. Follow-up of CD is needed to ensure response to symptoms, prevention of consequences, and continued maintenance of motivation to remain gluten free.

Discussions upon the issue of repeating duodenal biopsies were intense in our group. There is no conclusive evidence of the benefit of universal follow-up biopsy, and we were unable to reach a consensus. Some would undertake follow-up biopsies in all patients with CD after 2–5 years on a GFD (table 3). There are others who reserve follow-up biopsies for those in whom there are persistent and recurrent symptoms or those for whom the follow-up biopsies are necessary to help confirm the diagnosis in the setting of continued diagnostic uncertainty.

There are novel techniques that may enhance the sensitivity of endoscopic examination, of which the immunisation technique is probably the most feasible currently. An understanding of the precise value of various serologic strategies in the detection of CD is continuing to evolve, as are advances in therapies that may ultimately provide some mitigation of the impairment of the QoL that is inherent in a strict GFD.

Ultimately, this review should not be regarded as fixed. Instead it represents our understanding of what is best in adult CD management according to current knowledge. It is likely, and indeed we hope, that there will be substantial progress in diagnosis, evaluation and management of CD to reduce the burden on the patient and society. We anticipate that future updated versions of these guidelines will be based on evolving published literature that may have an audit or research base relevant to adult CD. Data in this review were mostly retrieved through searches of PubMed. We acknowledge that there are other medical databases and we cannot rule out that had we searched more than one database we may have identified additional relevant studies that have now been left out of this review.

Areas for future research

The panel of experts recognise that the main challenge in the future is to allocate available resources effectively to reduce the burden of disease from CD.

Future research should focus on the following areas:

- how to induce long-term remission without a GFD, that is, novel therapies and vaccine;
- better understanding of the disease processes, including genetics and antigen presentation;
- prevent and cure extra-intestinal manifestation and complications, including infections;
- be able to assess tolerable amount of gluten for individual patients;
- define the role of duodenal biopsy, serology and point of care testing at diagnosis and follow-up;
- find a robust and valid blood marker for diagnosis and monitoring of the disease;
- understand the pathogenesis of RCDI and II.

Author affiliations

1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
2Department of Paediatrics, Örebro University Hospital, Örebro, Sweden
3Department of Medicine, Dr C. Bonorino Udoundo Gastroenterology Hospital, Del Salvador University, Buenos Aires, Argentina
4Coeliac Centre/1st Department of Internal Medicine, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
5University of Nottingham, Department of Epidemiology and Public Health, Nottingham City Hospital, Nottingham, UK
6Department of Medicine and Surgery, University of Salerno, Salerno, Italy
7Gastroenterology, Division of Nutritional Sciences, King’s College London, The Payne Institute, St Thomas Hospital, London, UK
8Coeliac Disease Center at Columbia University, New York, New York, USA
9Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK
10Registered dietitian and representative of the British Dietetic Association, Bath, Somerset, UK
11Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
12School of Medicine, University of Tampere, Tampere, Finland
13Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland
14Department of Medicine, Seinäjoki Central Hospital, Finland
15Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
16Department of Dermatology, Imperial College NHS Healthcare Trust, St Mary’s Hospital, London, UK
17Department of Gastroenterology, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet, Oslo, Norway
18Coeliac UK, Apollo Centre, London, UK
19Patient Representative & Regional Chairman for Coeliac UK, Sheffield, UK
20Division of Gastroenterology and Hepatology, Department of Immunology Mayo Clinic, Rochester, Minnesota, USA
21School of Medicine, University of Salerno, Salerno, Italy
22Department of Gastroenterology and Liver Unit, Royal Hallamshire Hospital & University of Sheffield, Sheffield, UK

Acknowledgements We thank all the patients involved in the related focus groups and discussions.

Contributors JFL and DSS initiated the study. JFL coordinated the project and conducted the web surveys on CD. DSS supervised the project and served as the representative of the British Society of Gastroenterology (BSG). All authors contributed to the literature searches, contributed to the writing of the manuscript, and approved the final version of the manuscript.

Funding JFL was supported by the Swedish Research Council (522-ZA09-195) and the Swedish Society of Medicine while writing the draft of this paper. JCB was supported by Consejo en Investigacion en Salud GCABA. KK was supported by the Academy of Finland, the Competitive Research Funding of the Tampere University Hospital (9N062), and The Sigrid Juselius Foundation. JAM was supported by DK 57892. DSS has received an educational grant from Biocard and Simtomax to undertake an investigator-led research studies on CD and/or gluten sensitivity, and an educational grant from Dr Schär (a gluten-free food manufacturer) to undertake an investigator-led research study on gluten sensitivity.

Competing interests DAW, TRC; received grant support from Coeliac UK. PHRG; scientific advisory board of Alvine Pharmaceuticals and ImmusanT. DAL: Ironwood Pharmaceuticals, Alvine Therapeutics, Alba Pharmaceuticals, Shire Therapeutics, In Nova Diagnostics and CRICO Risk Management Foundation. JAM; consultant for Alba Pharmaceuticals, Alvine Therapeutics, Flamentera, 2GPharma Inc and ImmusanT. KEAL: ImmusanT, Regeneron and Alvine Pharmaceuticals. DSS: received educational grants from Coeliac UK, Biocard, Simtomax and Dr Schär (a gluten-free food manufacturer) to undertake an investigator-led research study on CD and/or gluten sensitivity.

Guidelines


Gut: first published as 10.1136/gutjnl-2013-306578 on 10 June 2014. Downloaded from http://gut.bmj.com/ on June 13, 2021 by guest. Protected by copyright.


